Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis (Secu_in_AD)
A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis
Sponsor: GWT-TUD GmbH
Listed as NCT03568136, this PHASE2 trial focuses on Dermatitis, Atopic and Eczema, Atopic and remains completed. Sponsored by GWT-TUD GmbH, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GWT-TUD GmbH
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .